Radnor Capital Management LLC Decreases Stock Holdings in The Clorox Company (NYSE:CLX)

Radnor Capital Management LLC reduced its stake in shares of The Clorox Company (NYSE:CLX) by 2.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,312 shares of the company’s stock after selling 80 shares during the period. Radnor Capital Management LLC’s holdings in Clorox were worth $538,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. State Street Corp boosted its stake in Clorox by 3.1% during the third quarter. State Street Corp now owns 8,182,109 shares of the company’s stock worth $1,332,947,000 after buying an additional 245,525 shares during the last quarter. Mizuho Securities USA LLC raised its holdings in shares of Clorox by 46,877.8% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock worth $733,095,000 after acquiring an additional 4,490,421 shares during the period. Geode Capital Management LLC boosted its position in shares of Clorox by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,028,333 shares of the company’s stock valued at $491,713,000 after acquiring an additional 33,970 shares during the last quarter. Stifel Financial Corp grew its holdings in shares of Clorox by 1.7% in the third quarter. Stifel Financial Corp now owns 2,334,826 shares of the company’s stock valued at $380,370,000 after purchasing an additional 37,967 shares during the period. Finally, Van ECK Associates Corp increased its position in Clorox by 2.2% during the third quarter. Van ECK Associates Corp now owns 1,492,717 shares of the company’s stock worth $237,372,000 after purchasing an additional 31,510 shares during the last quarter. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Clorox Stock Down 0.4 %

Shares of CLX opened at $158.43 on Thursday. The company’s 50-day simple moving average is $164.48 and its 200-day simple moving average is $156.16. The company has a debt-to-equity ratio of 11.08, a quick ratio of 0.62 and a current ratio of 1.00. The Clorox Company has a 1 year low of $127.60 and a 1 year high of $171.37. The stock has a market capitalization of $19.61 billion, a PE ratio of 55.20, a P/E/G ratio of 3.04 and a beta of 0.42.

Clorox (NYSE:CLX) last released its earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.50. The company had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The firm’s quarterly revenue was up 27.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.49 EPS. Analysts forecast that The Clorox Company will post 6.85 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 29th will be paid a dividend of $1.22 per share. The ex-dividend date is Wednesday, January 29th. This represents a $4.88 annualized dividend and a yield of 3.08%. Clorox’s payout ratio is 170.03%.

Analysts Set New Price Targets

Several research firms have weighed in on CLX. Evercore ISI decreased their target price on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a report on Monday, October 14th. DA Davidson increased their price objective on Clorox from $153.00 to $171.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Jefferies Financial Group raised Clorox from a “hold” rating to a “buy” rating and raised their target price for the stock from $174.00 to $187.00 in a research note on Tuesday, October 1st. TD Cowen raised Clorox from a “sell” rating to a “hold” rating and upped their price target for the company from $155.00 to $170.00 in a research note on Wednesday, November 6th. Finally, Barclays raised their price objective on Clorox from $137.00 to $139.00 and gave the stock an “underweight” rating in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $157.46.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.